Prognostic impact of peripheral artery disease in patients with and without high bleeding risk undergoing percutaneous coronary intervention

• Published in: Catheterization and cardiovascular interventions Vol. 103; no. 3; pp. 425 - 434
• Main Authors: Spirito, Alessandro, Cohen, Rebecca, Sartori, Samantha, Vogel, Birgit, Baber, Usman, Pileggi, Brunna, Smith, Kenneth, Nicosia, Danielle, Kamaleldin, Karim, Farhan, Serdar, Kini, Annapoorna, Sharma, Samin K, Dangas, George, Mehran, Roxana
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-02-2024
• Subjects: Angioplasty; Bleeding; Cardiovascular diseases; Cerebral infarction; Comorbidity; Coronary Artery Disease - chemically induced; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - therapy; Drug-Eluting Stents - adverse effects; Hemorrhage - chemically induced; Humans; Implants; Myocardial infarction; Percutaneous Coronary Intervention - adverse effects; Peripheral Arterial Disease - diagnosis; Peripheral Arterial Disease - therapy; Platelet Aggregation Inhibitors - adverse effects; Prognosis; Risk Factors; Treatment Outcome; Vascular diseases; Vein & artery diseases; percutaneous coronary intervention; bleeding; high bleeding risk; peripheral artery disease; outcomes
• ISSN: 1522-1946; 1522-726X
• DOI: 10.1002/ccd.30960

Peripheral artery disease (PAD) is associated with worse outcomes after percutaneous coronary intervention (PCI). The aim of this study was to assess the prognostic impact of PAD according to high bleeding risk (HBR) status.
Consecutive patients undergoing PCI with drug-eluting stent implantation at a tertiary-care center (Mount Sinai Hospital) between 2012 and 2019 were stratified according to HBR and PAD status. The primary outcome was major adverse cardiac events (MACE), a composite of all-cause death, myocardial infarction (MI), and stroke 1 year after PCI. Secondary outcomes included major bleeding.
Out of 16,750 patients, 43% were HBR and 57% were no-HBR. Within the two groups, PAD patients were 14% and 6%, respectively, and were more likely to have comorbidities and to undergo complex PCI than no-PAD patients. Within the HBR group, PAD was associated with an increased risk of MACE (11.4% vs. 7.3%, hazard ratio [HR]: 1.59, 95% confidence interval [CI]: 1.27-1.99, p < 0.001) and a numerical nonsignificant increase of major bleeding (8.5% vs. 6.9%, HR: 1.25, 95% CI: 0.98-1.59, p = 0.066) as compared with no-PAD. Among no-HBR patients, rates of MACE and major bleeding were numerically but not significantly higher in the PAD group. After multivariable adjustment, PAD was no longer a predictor of adverse outcomes, irrespective of HBR status.
At 1-year after PCI, PAD was associated with increased 1-year risks of MACE in HBR patients. After adjustment for cardiovascular risk factors and comorbidities, the effect of PAD on adverse events was largely attenuated.